Myriad Genetics Q3 EPS Forecast Increased by Leerink Partnrs

Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) - Research analysts at Leerink Partnrs increased their Q3 2025 earnings per share estimates for shares of Myriad Genetics in a report issued on Monday, April 21st. Leerink Partnrs analyst P. Souda now forecasts that the company will earn ($0.05) per share for the quarter, up from their prior forecast of ($0.06). The consensus estimate for Myriad Genetics' current full-year earnings is ($0.30) per share. Leerink Partnrs also issued estimates for Myriad Genetics' FY2025 earnings at ($0.31) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.01) EPS and FY2026 earnings at ($0.14) EPS.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.12). Myriad Genetics had a negative net margin of 14.09% and a negative return on equity of 4.51%. The firm had revenue of $210.60 million during the quarter, compared to the consensus estimate of $210.35 million. During the same period in the previous year, the company posted ($0.12) EPS.

A number of other analysts have also recently commented on MYGN. Craig Hallum initiated coverage on shares of Myriad Genetics in a research report on Wednesday, February 12th. They issued a "buy" rating and a $29.00 price objective for the company. Bank of America dropped their target price on shares of Myriad Genetics from $13.00 to $11.00 and set an "underperform" rating for the company in a report on Monday, March 3rd. UBS Group decreased their price target on shares of Myriad Genetics from $18.00 to $16.00 and set a "neutral" rating for the company in a research report on Tuesday, February 25th. Scotiabank lowered their target price on Myriad Genetics from $24.00 to $20.00 and set a "sector outperform" rating for the company in a report on Tuesday, April 1st. Finally, Guggenheim lowered Myriad Genetics from a "buy" rating to a "neutral" rating in a report on Wednesday, April 9th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $20.61.

Myriad Genetics Stock Up 0.4 %

NASDAQ:MYGN opened at $7.43 on Wednesday. The stock has a 50-day simple moving average of $9.98 and a 200 day simple moving average of $14.06. Myriad Genetics has a 52-week low of $7.28 and a 52-week high of $29.30. The company has a market cap of $684.83 million, a PE ratio of -5.72 and a beta of 1.87. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90.

Hedge Funds Weigh In On Myriad Genetics

Large investors have recently modified their holdings of the company. D. E. Shaw & Co. Inc. raised its stake in shares of Myriad Genetics by 58.1% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,819,814 shares of the company's stock valued at $24,950,000 after acquiring an additional 668,429 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Myriad Genetics by 377.6% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 549,456 shares of the company's stock worth $7,533,000 after acquiring an additional 434,420 shares during the period. Artisan Partners Limited Partnership boosted its stake in shares of Myriad Genetics by 13.9% during the 4th quarter. Artisan Partners Limited Partnership now owns 2,766,729 shares of the company's stock worth $37,932,000 after acquiring an additional 336,770 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Myriad Genetics by 87.4% in the 4th quarter. Renaissance Technologies LLC now owns 684,874 shares of the company's stock worth $9,390,000 after acquiring an additional 319,500 shares in the last quarter. Finally, Fisher Asset Management LLC raised its holdings in Myriad Genetics by 50.2% during the fourth quarter. Fisher Asset Management LLC now owns 905,209 shares of the company's stock valued at $12,410,000 after acquiring an additional 302,367 shares during the period. 99.02% of the stock is owned by hedge funds and other institutional investors.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.